Eurofins Viracor Company Profile

Background

Eurofins Viracor is a specialized diagnostic laboratory with over 40 years of expertise in infectious disease, immunology, and allergy testing, particularly for immunocompromised and critically ill patients. As a subsidiary of Eurofins Scientific, a global leader in bio-analytical testing, Eurofins Viracor is dedicated to delivering timely and accurate diagnostic information to healthcare providers, transplant teams, and biopharmaceutical companies. The company's mission is to improve lives, one test at a time, by providing innovative solutions and laboratory services that enhance patient care and advance scientific research.

Key Strategic Focus

Eurofins Viracor's strategic focus encompasses:

Infectious Disease Diagnostics: Offering a comprehensive menu of over 3,000 assays for detecting and monitoring viral, bacterial, and fungal pathogens.

Immunology and Allergy Testing: Providing specialized tests to assess immune function and identify allergic responses, aiding in the management of immunocompromised patients.

Transplant Diagnostics: Delivering critical testing services for pre- and post-transplant monitoring to ensure graft viability and patient health.

Biopharmaceutical Support: Partnering with pharmaceutical companies to perform essential clinical trial testing, as demonstrated in their collaboration with Moderna during the COVID-19 vaccine trials.

Financials and Funding

Eurofins Viracor operates as a subsidiary of Eurofins Scientific, which acquired the company in 2014 for $255 million. As part of the Eurofins network, Eurofins Viracor benefits from the financial stability and resources of its parent company, enabling continuous investment in research, development, and expansion of diagnostic services.

Pipeline Development

Eurofins Viracor is committed to advancing diagnostic solutions, with recent developments including:

Chagas Disease qPCR Assay: Launched in January 2025, this quantitative PCR assay enhances the detection of Trypanosoma cruzi, the causative agent of Chagas disease, providing rapid and accurate results within 48 hours.

CAR-T Cell Therapy Monitoring: In February 2023, the company introduced the ExPeCT™ CAR-T multiplexed quantitative real-time PCR assay, a groundbreaking test for assessing the expansion and persistence of CAR-T therapy in patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.

Technological Platform and Innovation

Eurofins Viracor distinguishes itself through proprietary technologies and innovative methodologies, including:

Dual-Gene Target qPCR Assays: Designed to reduce false negatives and under-quantification by targeting two regions within the pathogen genome, enhancing diagnostic accuracy.

Next-Generation Sequencing (NGS): Utilized for pathogen identification and resistance profiling, providing comprehensive insights into infectious agents.

Immunological Assays: Developed for monitoring immune function and transplant rejection, supporting personalized patient management.

Leadership Team

Eurofins Viracor's leadership comprises experienced professionals dedicated to advancing diagnostic excellence:

Michelle Altrich, PhD, HCLD (ABB): President. Dr. Altrich has held various roles within the company, including Chief Scientific Officer and Clinical Laboratory Director. She earned her PhD in pathology and microbiology from the University of Nebraska Medical Center, focusing on tumor immunology.

Brock Neil, PhD, BCLD (ABB): Clinical Laboratory Director. Dr. Neil oversees laboratory operations and compliance, with expertise in infectious disease diagnostics. He received his PhD in Microbiology from the University of Iowa, specializing in Neisseria meningitidis pathogenesis.

Rob Horel: Vice President of Sales and Marketing. Mr. Horel brings over two decades of commercial leadership experience, including roles at SOPHiA Genetics and as a Commissioned Officer in the U.S. Navy. He holds a BS in Mechanical Engineering from the U.S. Naval Academy.

Matt Schuman: Vice President of Laboratory Operations. Mr. Schuman has extensive experience in laboratory management across hospitals and reference laboratories. He holds a BS in Medical Technology from the University of Nebraska Medical Center and an MBA from Benedictine College.

Steven Kleiboeker, DVM, PhD, HCLD: Vice President of Research & Development. Dr. Kleiboeker oversees the company's research programs and has served as principal investigator on numerous government-funded grants. He earned his DVM and PhD from the University of Missouri.

Leadership Changes

In May 2021, Rob Horel rejoined Eurofins Viracor as Vice President of Sales and Marketing, bringing extensive experience in commercial leadership and a passion for improving patient lives.

Competitor Profile

Market Insights and Dynamics

The diagnostic laboratory industry is characterized by rapid technological advancements and a growing emphasis on personalized medicine. The demand for specialized testing services, particularly in infectious diseases and immunology, continues to rise, driven by the increasing prevalence of chronic diseases and the need for precise diagnostics.

Competitor Analysis

Key competitors in the specialized diagnostic testing market include:

Quest Diagnostics: A leading provider of diagnostic information services, offering a broad range of tests across various medical conditions.

LabCorp: Provides comprehensive laboratory services, including specialized testing in oncology, genetics, and infectious diseases.

ARUP Laboratories: A national reference laboratory offering extensive diagnostic testing services, with a focus on complex and esoteric tests.

Mayo Clinic Laboratories: Offers a wide array of specialized tests, leveraging the clinical expertise of the Mayo Clinic.

Strategic Collaborations and Partnerships

Eurofins Viracor has established significant collaborations to enhance its diagnostic capabilities:

Moderna Partnership: During the COVID-19 pandemic, Eurofins Viracor partnered with Moderna to perform essential clinical trial testing for the mRNA-1273 COVID-19 vaccine candidate, contributing to the vaccine's successful development and approval.

Operational Insights

Eurofins Viracor's strategic considerations include:

Quality and Compliance: Adherence to rigorous quality standards, including CLIA certification and CAP accreditation, ensuring reliable and accurate test results.

Technological Innovation: Continuous investment in research and development to introduce advanced diagnostic assays and methodologies.

Customer-Centric Approach: Commitment to providing timely and actionable diagnostic information, supporting healthcare providers in delivering optimal patient care.

Strategic Opportunities and Future Directions

Eurofins Viracor is poised to capitalize on several strategic opportunities:

Expansion of Test Menu: Developing new assays to address emerging infectious diseases and expanding capabilities in personalized medicine.

Global Reach: Leveraging the Eurofins network to extend services to international markets, meeting the growing demand for specialized diagnostics.

Technological Advancements: Investing in cutting-edge technologies, such as artificial intelligence and machine learning, to enhance diagnostic accuracy and efficiency.